Bencze Syndrome

Bencze syndrome is an extremely rare birth condition. It causes one side of the face to grow a little more than the other, and it often appears together with crossed eyes (a type of strabismus). Doctors sometimes call it hemifacial hyperplasia with strabismus. In Bencze syndrome, the facial skeleton (the bones of the face) and soft tissues (skin, fat, muscle) on one side become bigger. The skull vault and the eyeballs themselves are usually normal. Children may show esotropia (an inward turning eye), amblyopia (a “lazy eye”), and sometimes a submucous cleft palate. Early reports suggested autosomal dominant inheritance in some families. Very few cases have ever been described, and there have been no new detailed case descriptions since 1979, so most of what we know comes from the original reports and from broader research on hemifacial overgrowth disorders. GARD Information Center+2NCBI+2

Bencze syndrome (also called hemifacial hyperplasia with strabismus) is a very rare inherited condition. A person has mild facial asymmetry (one side of the face grows more than the other), but the neurocranium and the eyeballs themselves are usually normal. The eye position can be misaligned (esotropia or convergent strabismus) and one eye may see less clearly (amblyopia). A submucous cleft palate can sometimes be present. Reported inheritance is autosomal dominant. Only a handful of cases have been described, and medical sources note no further detailed reports after 1979, so today’s care focuses on treating the individual features rather than the syndrome as a whole. Wiley Online Library+4GARD Information Center+4orpha.net+4

Other names

• Hemifacial hyperplasia with strabismus

• Hemifacial hyperplasia–strabismus syndrome

• Oculofacial (hemifacial) hyperplasia with esotropia/amblyopia
  These names all describe the same core picture: mild one-sided facial overgrowth with eye misalignment. GARD Information Center+1

Types

Because literature is limited, doctors use the language of hemifacial hyperplasia to describe types:

1. True hemifacial hyperplasia – both the hard tissues (bones, teeth) and soft tissues on one side are enlarged.

2. Partial hemifacial hyperplasia – only some structures are enlarged (for example, soft tissues more than bone, or teeth more than jaw).

3. Predominantly muscular enlargement – muscle bulk is the main change.

4. Predominantly fatty/fibroadipose enlargement – fat-rich soft tissue is the main change.

5. With dental involvement – macrodontia (larger teeth), altered bite, or dental crowding on the larger side.

6. With temporomandibular joint (TMJ)/condylar overgrowth – jaw joint changes drive asymmetry.

These “types” are descriptive, not strict categories. They help plan care (eye care, orthodontics, or surgery) rather than define separate diseases. oooojournal.net+2ScienceDirect+2

Causes

No single confirmed cause exists for Bencze syndrome. The list below gathers plausible mechanisms and associations drawn from the original Bencze families and from modern science on related hemifacial overgrowth conditions. Each item is written as a hypothesis or contributor, not a proven fact for every patient.

1. Autosomal dominant inheritance in some families. The original report showed parent-to-child transmission with facial asymmetry and strabismus, suggesting a dominantly inherited trait in that family. PubMed

2. Somatic mosaic mutations in growth-pathway genes. In related hemifacial overgrowth disorders, scientists have found PIK3CA mutations in affected tissues. Mosaic means only some cells carry the change, which can make one side grow more. PMC+1

3. PI3K–AKT–mTOR pathway over-activation. This pathway controls cell growth. When it is overactive in a patch of facial tissue, that patch can overgrow. (Evidence strong in related conditions; unproven but possible in Bencze syndrome.) PMC

4. Segmental developmental “field” error. Early facial development is organized in fields. A field error on one side can produce stable, one-sided overgrowth. PMC

5. Neural crest migration imbalance. Facial bones and tissues come from neural crest cells. A local imbalance could enlarge one side. (Conceptual model from craniofacial biology.) PMC

6. Localized muscle overgrowth. In some patients the muscles on one side are larger, contributing to asymmetry. PMC

7. Localized fat/fibroadipose overgrowth. Some patients show fatty tissue expansion (facial infiltrating lipomatosis) as part of the picture. BioMed Central

8. Condylar hyperplasia of the mandible. Overgrowth of the jaw joint (condyle) can tilt the bite and enlarge one side of the lower face. ScienceDirect

9. Abnormal local blood or lymph flow during development. Vascular or lymphatic differences can change growth signals in a region and drive overgrowth. (Model drawn from overgrowth/vascular malformation literature.) ERN Skin

10. Prenatal micro-trauma hypothesis. Some authors have suggested minor prenatal injuries to developing tissues might trigger localized overgrowth, though evidence is weak. ScienceDirect

11. Hormonal micro-environment effects. Tissue sensitivity to growth factors on one side could promote asymmetric growth. (Theories appear in craniofacial asymmetry reviews.) ScienceDirect

12. Local stem/progenitor cell dysregulation. If stem cells in a small area divide more, that region becomes larger. (Mechanistic model consistent with mosaic overgrowth biology.) Cell

13. Bone remodeling bias. One jaw condyle may grow longer or remodel faster, shifting the face. ijoms.com

14. Dental eruption asymmetry. Larger or earlier-erupting teeth on one side can push the bite and jaw position toward that side. joms.org

15. Soft-tissue fibrosis with fat proliferation. Some hemifacial cases show infiltrating fatty tissue that resists normal surgical control. ajnr.org

16. Connective-tissue matrix differences. Small differences in collagen/elastic fibers can change tissue volume and stretch. (Proposed in case discussions.) PMC

17. Eye-muscle imbalance leading to strabismus. When extraocular muscles pull unevenly, eyes turn inward (esotropia). In Bencze syndrome, strabismus is part of the syndrome rather than a separate disease. GARD Information Center

18. Amblyopia from constant eye turn. A turned eye can reduce visual input to the brain, leading to a “lazy eye” if not treated early. GARD Information Center

19. Submucous cleft palate as a midline developmental variant. A hidden cleft under the palate lining can co-occur in some patients and may affect speech or ear function. GARD Information Center

20. Unknown/idiopathic factors. Many patients have no identifiable trigger even after imaging and genetic tests. The condition is ultra-rare, and evidence is limited. GARD Information Center

Common symptoms and signs

1. Mild facial asymmetry. One cheek/jaw looks fuller or longer. It may be subtle in childhood and more obvious during growth spurts. GARD Information Center

2. Esotropia (inward eye turn). One eye turns inward, some or all of the time. Parents may notice the eye “crossing,” especially when the child is tired or focusing on near tasks. GARD Information Center

3. Amblyopia (lazy eye). The brain favors the straight eye and “suppresses” the turned eye, lowering vision if not treated early. GARD Information Center

4. Convergent strabismus with limited binocular vision. The eyes do not point in the same direction, reducing depth perception and 3-D vision. GARD Information Center

5. Submucous cleft palate (sometimes). The roof of the mouth looks intact, but the muscles under the lining are split, causing nasal speech or middle-ear issues in some children. GARD Information Center

6. Jaw size difference. One side of the lower face may be longer or wider; the chin can deviate. Bite may not meet evenly. Lippincott Journals

7. Dental changes. Larger teeth (macrodontia) or crowding on the larger side can appear, along with an occlusal cant (tilt of the bite plane). oooojournal.net

8. Chewing difficulty. Uneven teeth contacts and jaw position can make chewing less efficient. joms.org

9. Speech differences (if palate involved). Submucous cleft can cause hypernasal speech or articulation issues. GARD Information Center

10. Eye strain and headaches. Constant eye turning can cause fatigue or frontal headaches. GARD Information Center

11. Reduced depth perception. When the eyes do not align, judging distance can be harder, affecting sports and some tasks. GARD Information Center

12. Psychosocial impact. Visible asymmetry or eye turning can affect self-confidence, especially in teens. (General effect noted across craniofacial differences.) Lippincott Journals

13. TMJ clicking or discomfort (in some). Bite mismatch can stress the jaw joints and muscles. joms.org

14. Nasal airflow difference (occasionally). Side-to-side tissue imbalance may change nasal airflow or septal position. (Clinical observation in hemifacial asymmetry care.) ScienceDirect

15. Stable course after growth. Asymmetry often stabilizes when facial growth ends; many cases require no urgent surgery, only monitoring and eye care. Synapse

Diagnostic evaluation

Important note: There is no single lab test that “proves” Bencze syndrome. Diagnosis is clinical: history, examination, eye alignment testing, and imaging to map jaw/face structures. Genetic testing of affected tissue may be considered when a mosaic overgrowth disorder is suspected. ScienceDirect

A) Physical examination

1. Craniofacial inspection and measurements. The clinician compares left vs right facial height, width, and projection, and tracks changes over time to confirm a stable, one-sided pattern. Wiley Online Library

2. Dental and bite evaluation. The dentist or maxillofacial surgeon checks molar/canine relationships, overbite/overjet, occlusal cant, and tooth size differences. joms.org

3. TMJ palpation and range of motion. Clicking, deviation on opening, or tenderness may suggest condylar overgrowth on one side. joms.org

4. Soft-tissue palpation. The doctor feels for thicker muscle or fatty tissue on the larger side and checks skin temperature and texture. Lippincott Journals

5. Ocular alignment assessment. A pediatric ophthalmologist evaluates eye position in all gaze directions to document esotropia. GARD Information Center

6. Visual acuity testing. Vision in each eye is measured to look for amblyopia and to guide treatment. GARD Information Center

7. Palate examination for submucous cleft. The clinician looks for a bifid uvula, translucent midline zone, and a notch in the back of the hard palate. GARD Information Center

8. Growth and development review. Height, weight, and developmental milestones are checked; intelligence is usually normal in the reported families. Synapse

B) Manual/bedside ophthalmic tests

9. Cover–uncover test. Covering one eye and uncovering it shows whether the fellow eye moves to pick up fixation, indicating a tropia (constant misalignment). GARD Information Center

10. Alternate cover test with prisms. Moving the cover from eye to eye breaks fusion and reveals the full angle of deviation; prisms measure the size in prism-diopters. GARD Information Center

11. Hirschberg corneal light reflex. A penlight reflection on the cornea helps screen the direction and size of an eye turn in young children. GARD Information Center

12. Krimsky test. Prisms are added in front of the eye until the corneal light reflex is centered, giving a quick alignment estimate. GARD Information Center

13. Stereoacuity cards (depth perception). Simple picture-based tests (e.g., fly or circles) show whether binocular depth vision is present. GARD Information Center

C) Laboratory and pathological tests

14. Targeted genetic testing of affected tissue (when suspected). In broader hemifacial overgrowth, PIK3CA mutations are often mosaic and may only be found in biopsied overgrown tissue, not blood. A positive result supports a mosaic overgrowth mechanism, which can guide counseling and research. ScienceDirect

15. Syndrome/differential work-up as needed. If features suggest another condition (e.g., Beckwith-Wiedemann spectrum, PROS), clinicians may order methylation studies or overgrowth panels, based on phenotype. (General overgrowth diagnostic approach.) understandingpros.com

16. Routine labs (usually normal). Blood counts and chemistries are typically normal and mainly rule out other causes; there is no specific blood marker for Bencze syndrome. GARD Information Center

D) Electrodiagnostic tests

17. Visual evoked potentials (VEP) (select cases). If vision loss seems out of proportion to amblyopia, VEP can check the visual pathway response from each eye. This is rarely needed but can help complex cases. (General ophthalmic practice.) GARD Information Center

18. Electromyography (EMG) of facial muscles (research/complex cases). When muscle hypertrophy is suspected, EMG can explore muscle activity differences, though it is not routine. (Used in related myohyperplasia research.) PMC

E) Imaging tests

19. 3-D CT or cone-beam CT of the facial skeleton. Maps bone asymmetry, condylar size, dental roots, and bite relationships; helps plan orthodontics or surgery. joms.org

20. MRI of face and orbits. Defines soft tissues (muscle vs fat), nerves, and eye muscles; helpful when infiltrating fat or unusual soft-tissue patterns are suspected. ajnr.org

21. Cephalometric analysis. Side-view X-ray measurements show how the jaws relate to the skull base and how the bite tilts. joms.org

22. Panoramic dental radiograph (OPG). Screens both jaws for tooth size, eruption, and asymmetry. joms.org

23. Serial photographic analysis. Standardized photos over time help document stability or progression through growth. (Common craniofacial practice.) Lippincott Journals

Non-pharmacological treatments (therapies & other measures)

1. Full eye exam and glasses
   Description: A pediatric/strabismus ophthalmologist checks vision in each eye, alignment, binocular function, and depth perception. Correcting refractive errors with glasses is step one for amblyopia and strabismus care. Purpose: Give the retina a sharp image and reduce strain that can worsen misalignment. Mechanism: Proper focus reduces the brain’s need to suppress a blurry eye and helps both eyes send clearer signals for binocular vision. Medscape

2. Occlusion therapy (patching)
   Description: A patch covers the stronger eye for hours each day so the weaker eye works harder. Purpose: Improve vision in the amblyopic eye. Mechanism: “Use-dependent” neuroplasticity—forcing the brain to process input from the weaker eye strengthens its visual pathway. Evidence shows patching and atropine penalization produce similar vision gains; adherence matters. Cochrane+2PMC+2

3. Near-vision activities during therapy
   Description: Reading, puzzles, coloring, or tablet tasks while patching help stimulate the weaker eye. Purpose: Increase therapy effectiveness. Mechanism: Focused near tasks add structured visual demand, engaging cortical circuits for clarity and eye-hand coordination. Medscape

4. Orthoptic/vision therapy exercises (selected cases)
   Description: Office-based or home exercises prescribed by strabismus specialists to support fusion, convergence, and accommodation. Purpose: Improve control in small-angle deviations and reduce asthenopia. Mechanism: Repetitive binocular tasks strengthen vergence control and sensory fusion. (Usually adjunctive; not a substitute for amblyopia therapy or surgery when indicated.) American Academy of Ophthalmology

5. Prism lenses
   Description: Prisms in glasses bend light to assist alignment for small residual deviations or postoperative diplopia. Purpose: Improve single binocular vision and comfort. Mechanism: Image-shifting lets the brain fuse inputs more easily, decreasing double vision. American Academy of Ophthalmology

6. Digital binocular treatments (select, adjunctive)
   Description: Some programs show movies/games separately to each eye to balance input. Purpose: Encourage binocular use and potentially improve adherence. Mechanism: Dichoptic presentation reduces suppression of the weaker eye. Evidence is evolving and mixed; classic patching/atropine remain standards. Cochrane+1

7. Sun protection & eye safety
   Description: Sunglasses and protective eyewear for sports. Purpose: Comfort and injury prevention, especially when one eye has reduced acuity. Mechanism: UV filtering and impact protection preserve vision in the better-seeing eye. Medscape

8. Psychosocial support and counseling
   Description: Support for child/family coping with patching, eye drops, cosmetic asymmetry, or surgery. Purpose: Improve adherence and reduce stigma or treatment fatigue. Mechanism: Education and behavioral strategies increase compliance (key to vision gains). JAMA Network

9. Speech-language therapy (if submucous cleft palate with VPI)
   Description: Targeted therapy for hypernasal speech or articulation. Purpose: Improve speech intelligibility and resonance. Mechanism: Motor-speech training and compensatory techniques while surgical plans are considered. PMC

10. Cleft/ENT team evaluation
    Description: Multidisciplinary assessment of submucous cleft and velopharyngeal competence. Purpose: Plan conservative or surgical management. Mechanism: Team care coordinates imaging, speech assessment, and timing of intervention. PMC

11. Nasal/voice hygiene and therapy for VPI
    Description: Techniques to lessen air escape and strain. Purpose: Support speech while awaiting or avoiding surgery. Mechanism: Behavioral strategies optimize velopharyngeal closure patterns in mild cases. PMC

12. Cosmetic counseling & photography tracking
    Description: Standardized photos and growth-tracking to document facial asymmetry. Purpose: Shared understanding of severity and change over time. Mechanism: Objective records guide timing of any cosmetic or orthognathic options later. GARD Information Center

13. Orthognathic/maxillofacial consult (adolescence/adult)
    Description: For persistent, functionally significant jaw/facial imbalance. Purpose: Plan corrective procedures when growth is complete. Mechanism: Skeletal realignment can improve occlusion and facial balance when indicated. (Case-by-case.) GARD Information Center

14. Healthy sleep and screen-break routines
    Description: Age-appropriate sleep and 20-20-20 breaks with near work. Purpose: Reduce eye strain and support therapy adherence. Mechanism: Rested visual systems tolerate patching/exercises better. Medscape

15. Regular follow-up schedule
    Description: Timed visits to titrate patching hours, adjust prisms, or plan surgery. Purpose: Catch regression early; optimize gains. Mechanism: Objective measures (visual acuity, prism diopters) guide stepwise care. Medscape

16. School accommodations
    Description: Seating, extra time for reading during patching periods. Purpose: Maintain learning while vision improves. Mechanism: Reduces functional impact during therapy. JAMA Network

17. General pediatric wellness
    Description: Routine vaccinations, nutrition, and growth checks. Purpose: Support overall development that indirectly benefits therapy success. Mechanism: Systemic health supports neural plasticity and participation. Medscape

18. Avoid unproven “stem-cell” clinics
    Description: Do not pursue cash-pay regenerative eye injections. Purpose: Safety. Mechanism: FDA warns most marketed stem-cell “treatments” are illegal/unapproved and have caused blindness and infections. U.S. Food and Drug Administration+2U.S. Food and Drug Administration+2

19. Family genetic counseling (as available)
    Description: Review inheritance, variants, and family planning questions. Purpose: Clarify risks and expectations. Mechanism: Pedigree-based counseling for suspected autosomal dominant traits. GARD Information Center

20. Lifestyle for eye comfort
    Description: Good lighting, regular outdoor time, and breaks with near tasks. Purpose: Reduce visual fatigue. Mechanism: Balanced visual demand supports sustained therapy. Medscape

---

Drug treatments

There are no FDA-approved drugs for “Bencze syndrome” itself. Medicines are used to manage features (strabismus procedures, amblyopia penalization, surgical care). Where I cite accessdata.fda.gov, the drug is FDA-approved for its labeled indication; some uses below (e.g., atropine for amblyopia penalization) are off-label and supported by ophthalmology evidence.

1. OnabotulinumtoxinA (BOTOX®) – labeled for strabismus
   Class: Neurotoxin (local chemodenervation). Dosage/Time: Injected into extraocular muscle; dosing individualized by muscle and deviation; effect builds over days and lasts weeks to months. Purpose: Temporarily weaken an overacting muscle to help realign the eyes or as a test before surgery. Mechanism: Blocks presynaptic acetylcholine release, relaxing the targeted muscle. Side effects: Ptosis, vertical deviations, dry eye, rare systemic spread symptoms; ocular puncture risk. FDA labeling specifically includes strabismus in patients ≥12 years. FDA Access Data+2FDA Access Data+2

2. Atropine sulfate 1% ophthalmic (off-label for amblyopia penalization)
   Class: Antimuscarinic mydriatic/cycloplegic. Dosage/Time: Typically 1% drop in the better eye daily or weekends per protocol; duration months, titrated by response. Purpose: Blur the better eye to force use of the amblyopic eye (alternative to patching). Mechanism: Paralyzes accommodation and dilates pupil in the treated eye, reducing near clarity. Side effects: Light sensitivity, near blur, rare systemic anticholinergic effects. FDA label covers mydriasis/cycloplegia; amblyopia use is off-label but supported by randomized trials and Cochrane reviews. FDA Access Data+2PMC+2

3. Phenylephrine ophthalmic (2.5–10%)
   Class: α1-agonist mydriatic. Dosage/Time: Pre-op/diagnostic dilation per label. Purpose: Facilitate exams or surgery planning. Mechanism: Iris dilator stimulation; vasoconstriction. Side effects: Elevated blood pressure risk with 10% in susceptible patients; local irritation. FDA Access Data+1

4. Cyclopentolate ophthalmic
   Class: Antimuscarinic cycloplegic. Dosage/Time: Pre-exam cycloplegia in children to measure accurate refraction. Purpose: Essential to prescribe correct glasses for amblyopia/strabismus care. Mechanism: Temporarily paralyzes accommodation. Side effects: Transient stinging, light sensitivity; rare systemic effects in young children. FDA Access Data

5. Tropicamide ophthalmic (alone or MYDCOMBI® with phenylephrine)
   Class: Antimuscarinic mydriatic. Dosage/Time: Diagnostic dilation. Purpose: High-quality retinal/optic nerve exam before therapy or surgery. Mechanism: Sphincter iris blockade. Side effects: Light sensitivity, blur. (MYDCOMBI is an FDA-approved phenylephrine+tropicamide spray.) FDA Access Data

6. Lubricating eye drops/ointments
   Class: Ocular surface protectants. Dosage/Time: PRN for irritation with patching or after procedures. Purpose/Mechanism: Improve tear film to reduce discomfort; support adherence. Side effects: Minimal. (General standard care.) Medscape

7. Topical anesthetic (for procedures only; not home use)
   Class: Local ocular anesthetic (e.g., proparacaine, tetracaine). Purpose: Short-term anesthesia for office procedures. Mechanism: Sodium-channel block. Side effects: Epithelial toxicity if misused; not for chronic use. (Labeling varies.) Medscape

8. Post-op antibiotic drops (e.g., ofloxacin 0.3%)
   Class: Fluoroquinolone antibiotic. Dosage/Time: Short course per surgeon after eye muscle or palate procedures if indicated. Purpose: Reduce infection risk. Mechanism: Inhibits bacterial DNA gyrase. Side effects: Local irritation; allergy. (Ofloxacin ophthalmic is FDA-approved for ocular infections.) FDA Access Data+1

9. Post-op anti-inflammatory drops (e.g., topical NSAID or steroid as directed)
   Class: Ocular anti-inflammatory. Purpose/Mechanism: Reduce post-operative inflammation and pain. Side effects: IOP rise with steroids; corneal risk with prolonged NSAIDs—use only as prescribed. (Label-specific.) Medscape

10. Analgesics (acetaminophen/ibuprofen, age-appropriate)
    Class: Analgesic/NSAID. Purpose: Short-term pain relief after surgery. Mechanism: Central analgesia and COX inhibition. Side effects: GI upset with NSAIDs; dosing safety essential. (Standard pediatric guidance.) Medscape

11. Antibiotic prophylaxis for palate surgery (per surgeon protocol)
    Class: Systemic antibiotics when indicated. Purpose: Surgical site infection prevention in select cases. Mechanism: Reduces bacterial load. Side effects: Allergy, GI upset. (Procedure-specific.) PMC

12. Decongestant/analgesic after palate procedures (short course, as advised)
    Purpose: Comfort and airway care. Mechanism: Reduces mucosal edema and pain. Side effects: Label-specific cautions. PMC

13. Antiemetics post-anesthesia (as needed)
    Purpose: Reduce nausea/vomiting after general anesthesia. Mechanism: Dopamine/serotonin receptor blockade (drug-specific). Side effects: Sedation, EPS (rare with some). American Academy of Ophthalmology

14. Allergy control (if ocular surface sensitive during therapy)
    Class: Antihistamine/mast-cell stabilizer drops. Purpose: Reduce itch that interferes with patching. Mechanism: Histamine blockade and mast-cell stabilization. Side effects: Mild sting. Medscape

15. Nasal steroids (if chronic rhinitis worsens VPI symptoms; physician-directed)
    Purpose: Improve nasal airflow patterns for speech. Mechanism: Anti-inflammatory effect on nasal mucosa. Side effects: Nasal irritation, epistaxis. PMC

16. Artificial tears/gel at night with patching
    Purpose: Comfort and corneal surface protection. Mechanism: Prolongs tear residence time. Side effects: Temporary blur. Medscape

17. Short-term steroid/antibiotic ointments (post-op per surgeon)
    Purpose: Decrease inflammation and infection risk on surgical sites. Mechanism: Local antimicrobial plus steroid. Side effects: IOP rise (ocular steroids), delayed healing—use as directed. American Academy of Ophthalmology

18. OnabotulinumtoxinA as a bridge/adjunct to surgery
    Purpose: Temporarily align eyes in select patterns or test fusion potential. Mechanism: Chemodenervation. Side effects: See Item 1. Evidence: FDA-labeled for strabismus; clinical studies show improvement in many patients. FDA Access Data+1

19. Cycloplegic refraction agents (tropicamide/cyclopentolate) for accurate prescribing
    Purpose: Ensure exact glasses prescription. Mechanism: Temporarily stops accommodation. Side effects: Light sensitivity. FDA Access Data+1

20. Phenylephrine (with tropicamide) to assist detailed pre-op exams
    Purpose: Maximal dilation for retina/nerve and alignment planning. Mechanism: α1-agonist mydriasis. Side effects: See Item 3. FDA Access Data

---

Dietary molecular supplements

These do not treat Bencze syndrome. They may support general eye health. Discuss with clinicians, especially for children.

1. Lutein + Zeaxanthin – Carotenoids concentrated in the macula; may support retinal antioxidant defenses; foods: leafy greens, eggs. (Adjunct only.) Medscape

2. Omega-3 fatty acids (ALA/EPA/DHA) – May support tear film and retinal cell membranes; fish, flax. Medscape

3. Vitamin A (within safe limits) – Essential for phototransduction; avoid excess. Medscape

4. Vitamin D (correct deficiency) – General neuromuscular/immune support; check levels. Medscape

5. Vitamin B12 & Folate – Correct deficiency to support neural pathways. Medscape

6. Zinc – Cofactor in retinal enzymes; avoid high-dose chronic use. Medscape

7. Vitamin C & E – Antioxidants for general ocular health; food-first approach. Medscape

8. Astaxanthin – Antioxidant studied for eye fatigue; evidence mixed. Medscape

9. Taurine – Abundant in retina; role supportive; data in children limited. Medscape

10. Probiotics (general wellness) – Gut-eye axis research is emerging; not a treatment. Medscape

---

Immunity-booster / regenerative / stem-cell drugs

Important safety note: There are no FDA-approved stem-cell or regenerative drugs for Bencze syndrome, strabismus, amblyopia, or submucous cleft palate. The only FDA-approved stem-cell products in the U.S. are cord-blood hematopoietic cells for blood disorders—not eye or craniofacial conditions. Avoid clinics selling unapproved “stem-cell” eye injections; such interventions have caused blindness and infections. U.S. Food and Drug Administration+2U.S. Food and Drug Administration+2

• Therefore, instead of listing nonexistent “stem-cell drugs” for this condition, clinicians focus on the evidence-based measures above. If you see any clinic advertise stem-cells for amblyopia/strabismus/facial asymmetry, treat that as a red flag and consult your ophthalmologist or cleft team. U.S. Food and Drug Administration

---

Surgeries

1. Strabismus surgery – rectus muscle recession
   Procedure: Detach an overacting extraocular muscle (e.g., medial rectus) and reattach it further back on the eye to weaken it. Why: To correct inward deviation (esotropia) and restore binocular alignment. Evidence: Standard, widely used approach; adjustable sutures may fine-tune alignment post-op. American Academy of Ophthalmology+1

2. Strabismus surgery – rectus muscle resection/plication
   Procedure: Shorten or fold a weaker muscle to strengthen its pull. Why: To balance forces and straighten the eyes, often combined with recession on the antagonist. Evidence: Classic, effective techniques with comparable outcomes in horizontal strabismus. PMC+1

3. Minimally invasive strabismus surgery (MISS) – selected centers
   Procedure: Smaller incisions to access muscles. Why: Potentially less tissue trauma and quicker recovery while achieving similar alignment. Evidence: Technique description and early outcomes published; surgeon-dependent. Wikipedia

4. Chemodenervation (botulinum toxin) as a procedure
   Procedure: Targeted onabotulinumtoxinA injection into a muscle. Why: Temporary alignment, diagnostic test of fusion, or bridge to surgery. Evidence: FDA-labeled for strabismus; many improve alignment within 6 months. FDA Access Data

5. Furlow double-opposing Z-palatoplasty (for submucous cleft palate with VPI)
   Procedure: Re-orient and lengthen the soft palate muscles using opposing Z-plasties. Why: Improve velopharyngeal closure to reduce hypernasality and improve speech. Evidence: Multiple series and reviews support effectiveness when indicated. PMC+2PubMed+2

---

Preventions

1. Early vision screening and prompt referral to pediatric ophthalmology. Medscape

2. Wear prescribed glasses consistently. Medscape

3. Follow patching/atropine schedules exactly—adherence drives results. PMC

4. Protect eyes during sports—use certified protective eyewear. Medscape

5. Keep post-op follow-ups to catch under/over-correction early. American Academy of Ophthalmology

6. Optimize general child health (sleep, nutrition, vaccines). Medscape

7. Avoid unregulated regenerative/stem-cell clinics. U.S. Food and Drug Administration

8. Use sun protection to reduce photophobia from mydriatic drops. FDA Access Data

9. In school, arrange accommodations during active therapy. JAMA Network

10. Seek speech-language evaluation early if speech is hypernasal. PMC

---

When to see a doctor

• Eyes that do not point in the same direction (constant or frequent).

• Covering one eye, squinting, or head turning to see.

• Poor vision in one eye found on screening or complaints of double vision.

• Hypernasal speech or nasal air escape on certain sounds.

• Any regression after stopping patching/atropine or after surgery.

• Red flags: eye pain, sudden vision loss, severe light sensitivity after drops or injections, or signs of infection after surgery—urgent care needed. Medscape+1

---

What to eat and what to avoid

• Eat more: leafy greens (lutein/zeaxanthin), brightly colored vegetables/fruit (antioxidants), fish 1–2×/week (omega-3s), eggs (macular carotenoids), nuts/legumes (minerals), dairy or fortified alternatives (vitamin A/D as appropriate), and plenty of water. Why: Overall ocular health and general wellness that supports therapy participation. Medscape

• Limit/avoid: smoking and secondhand smoke (ocular surface irritation), ultra-processed foods high in sugar and trans-fats (systemic inflammation), energy drinks/caffeine excess in teens (sleep disruption). Why: Irritation and poor sleep can reduce therapy adherence. Medscape

---

FAQs

1. Is Bencze syndrome common?
   No. It’s extremely rare, with few published cases and no new detailed case series since 1979. GARD Information Center

2. Is there a gene test?
   Inheritance was described as autosomal dominant, but no specific gene is established in public sources; management is clinical. GARD Information Center

3. Will glasses cure it?
   Glasses don’t “cure” the syndrome but are essential to optimize focus and support amblyopia/strabismus treatment. Medscape

4. Which is better—patching or atropine?
   Both improve vision; studies and Cochrane reviews show similar effectiveness. Choice depends on age, severity, and family preference. Cochrane+1

5. Is atropine for amblyopia FDA-approved?
   No. The FDA label is for mydriasis/cycloplegia; amblyopia penalization is off-label but evidence-based. FDA Access Data+1

6. Are there FDA-approved drugs for the whole syndrome?
   No. Care targets features (e.g., strabismus), not the syndrome itself. GARD Information Center

7. Does botulinum toxin help strabismus?
   Yes, it is FDA-labeled for strabismus in appropriate patients. FDA Access Data

8. Will my child need surgery?
   Some children do, especially if significant misalignment persists after conservative care; surgeons choose recession/resection techniques as needed. American Academy of Ophthalmology

9. Can digital binocular games replace patching?
   Not yet. Evidence is evolving; patching/atropine remain gold standards. Cochrane

10. Does facial asymmetry get worse?
    Typically mild and mainly cosmetic; growth tracking guides if later maxillofacial options are needed. GARD Information Center

11. Can speech therapy fix a submucous cleft palate?
    Therapy helps, but significant velopharyngeal insufficiency may need Furlow palatoplasty. PMC

12. Are “stem-cell” injections for amblyopia or strabismus safe?
    No. Such treatments are not approved and have caused harm; avoid them. U.S. Food and Drug Administration

13. How long does amblyopia treatment take?
    Months, with close follow-up; progress slows if adherence drops. PMC

14. Will treatment affect school?
    Temporary adjustments (seating, extra time) help during patching/atropine. JAMA Network

15. Who should be on our care team?
    Pediatric/strabismus ophthalmologist, optometrist, orthoptist, speech-language pathologist (if palate issues), and cleft/ENT team as needed. AAPOS+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 20, 2025.

PDF Documents For This Disease Condition References